147 related articles for article (PubMed ID: 20117197)
21. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Bartos C; Ambrus R; Sipos P; Budai-Szűcs M; Csányi E; Gáspár R; Márki Á; Seres AB; Sztojkov-Ivanov A; Horváth T; Szabó-Révész P
Int J Pharm; 2015 Aug; 491(1-2):198-207. PubMed ID: 26142244
[TBL] [Abstract][Full Text] [Related]
22. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects.
Gschwend MH; Erenmemişoğlu A; Martin W; Tamur U; Kanzik I; Hincal AA
Arzneimittelforschung; 2007; 57(5):264-8. PubMed ID: 17598697
[TBL] [Abstract][Full Text] [Related]
24. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
[TBL] [Abstract][Full Text] [Related]
25. Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet.
Srivastava R; Kumar D; Pathak K
Int J Pharm; 2012 May; 427(2):153-62. PubMed ID: 22306039
[TBL] [Abstract][Full Text] [Related]
26. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations.
Hanft G; Türck D; Scheuerer S; Sigmund R
Inflamm Res; 2001 Mar; 50 Suppl 1():S35-7. PubMed ID: 11339520
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
Xu HY; Zhong DF; Zhao LM; Zhang YF; Zhang BJ
Yao Xue Xue Bao; 2001 Jan; 36(1):71-3. PubMed ID: 12579866
[TBL] [Abstract][Full Text] [Related]
28. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration.
Euller-Ziegler L; Vélicitat P; Bluhmki E; Türck D; Scheuerer S; Combe B
Inflamm Res; 2001 Mar; 50 Suppl 1():S5-9. PubMed ID: 11339521
[TBL] [Abstract][Full Text] [Related]
29. Solubility enhancement of Cox-2 inhibitors using various solvent systems.
Seedher N; Bhatia S
AAPS PharmSciTech; 2003; 4(3):E33. PubMed ID: 14621965
[TBL] [Abstract][Full Text] [Related]
30. Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs.
Shakeel F
Pharm Dev Technol; 2010; 15(2):131-8. PubMed ID: 19911951
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of intravenous and oral meloxicam in ruminant calves.
Coetzee JF; KuKanich B; Mosher R; Allen PS
Vet Ther; 2009; 10(4):E1-8. PubMed ID: 20425727
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.
Galia E; Nicolaides E; Hörter D; Löbenberg R; Reppas C; Dressman JB
Pharm Res; 1998 May; 15(5):698-705. PubMed ID: 9619777
[TBL] [Abstract][Full Text] [Related]
33. Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk.
Mishra DN; Vijaya Kumar SG
Yakugaku Zasshi; 2006 Jul; 126(7):495-8. PubMed ID: 16819271
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of meloxicam.
Türck D; Busch U; Heinzel G; Narjes H
Arzneimittelforschung; 1997 Mar; 47(3):253-8. PubMed ID: 9105543
[TBL] [Abstract][Full Text] [Related]
35. Soft, chewable gelatin-based pharmaceutical oral formulations: a technical approach.
Dille MJ; Hattrem MN; Draget KI
Pharm Dev Technol; 2018 Jun; 23(5):504-511. PubMed ID: 28532266
[TBL] [Abstract][Full Text] [Related]
36. Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors.
Ochi M; Kawachi T; Toita E; Hashimoto I; Yuminoki K; Onoue S; Hashimoto N
Int J Pharm; 2014 Oct; 474(1-2):151-6. PubMed ID: 25138254
[TBL] [Abstract][Full Text] [Related]
37. Strategies for meloxicam delivery to and across the skin: a review.
Chen J; Gao Y
Drug Deliv; 2016 Oct; 23(8):3146-3156. PubMed ID: 26956920
[TBL] [Abstract][Full Text] [Related]
38. In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets.
Gao C; Huang J; Jiao Y; Shan L; Liu Y; Li Y; Mei X
Int J Pharm; 2006 Sep; 322(1-2):104-12. PubMed ID: 16806752
[TBL] [Abstract][Full Text] [Related]
39. Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
Ochi M; Inoue R; Yamauchi Y; Yamada S; Onoue S
Pharm Res; 2013 Feb; 30(2):377-86. PubMed ID: 22983645
[TBL] [Abstract][Full Text] [Related]
40. Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus).
Carpenter JW; Pollock CG; Koch DE; Hunter RP
J Zoo Wildl Med; 2009 Dec; 40(4):601-6. PubMed ID: 20063804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
